

FDA's Critical Path Initiative and Translational Research

Janet Woodcock, MD
Acting Deputy commissioner for Operations, FDA

Delays and difficulties in translating new scientific discoveries into useful medical products has been well documented. Despite extensive investment in basic biomedical sciences, the problem has been worsening over the past decade. FDA's Critical Path Initiative is designed to address barriers resulting from under-investment in the scientific research and infrastructure needed to efficiently evaluate new drugs, devices and vaccines. The presentation will cover the background and recent progress in improving the Critical Path.